Business Context and Reporting Period
Company: NeuroBo Pharmaceuticals, Inc. (Note: Input metadata referenced "Metavia Inc.", but the filing text identifies the registrant as NeuroBo Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2024
Business Overview: NeuroBo is a clinical-stage biotechnology company focused on developing pharmaceuticals for cardiometabolic diseases, specifically metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Key programs include DA-1241 (GPR119 agonist) and DA-1726 (GLP-1/GCGR dual agonist). The company has no product revenue and relies on capital raising and licensing to fund operations.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(5.65) million | $(3.82) million | $(22.42) million | $(7.16) million |
| Loss Per Share (Basic/Diluted) | $(0.55) | $(0.75) | $(3.24) | $(1.41) |
| Operating Expenses | $6.26 million | $3.89 million | $23.22 million | $10.22 million |
| Research & Development | $4.52 million | $2.29 million | $17.50 million | $5.29 million |
| General & Administrative | $1.74 million | $1.60 million | $5.73 million | $4.93 million |
| Cash and Cash Equivalents (End of Period) | $21.67 million (as of Sept 30, 2024) | |||
| Accumulated Deficit | ||||
| Net Cash Used in Operating Activities (YTD) | $(19.28) million | |||
| Net Cash Provided by Financing Activities (YTD) | $18.52 million |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses increased by 60.8% in Q3 2024 compared to Q3 2023, driven primarily by a 97.1% increase in R&D expenses. This reflects the ramp-up of the Phase 2a clinical trial for DA-1241 and the Phase 1 trial for DA-1726.
- Financing Activity: In June 2024, the company closed a registered direct offering and private placement (the "Offering") raising gross proceeds of $20.0 million. This contrasts with no significant financing proceeds in the prior year period.
- Warrant Liability Fair Value: The company recorded a gain of $0.30 million in Q3 2024 related to the change in fair value of warrant liabilities, compared to a loss of $0.09 million in Q3 2023.
- Share Count: Weighted average shares outstanding increased significantly due to the June 2024 Offering and warrant exercises, rising from ~5.08 million in Q3 2023 to ~10.21 million in Q3 2024.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern within one year. With $21.7 million in cash, they believe funds are sufficient only through the third quarter of 2025. Continued funding via equity or debt is required.
- Clinical Milestones:
- DA-1241: Phase 2a trial for MASH completed last patient last visit in October 2024; top-line results expected in December 2024.
- DA-1726: Phase 1 SAD study completed with positive safety data. MAD study enrollment ongoing; top-line data expected in Q1 2025.
- Strategic Developments: In July 2024, the company out-licensed NB-01 (for painful diabetic neuropathy) to MThera Pharma. In August 2024, a joint research agreement was signed with ImmunoForge for a long-acting formulation of DA-1726.
- Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of September 30, 2024, due to material weaknesses in internal control over financial reporting (segregation of duties, logical access, and supervision). Remediation efforts are underway.
- Risks: Risks include failure to secure additional financing, potential dilution from future equity offerings, and the inherent uncertainties of clinical trial outcomes.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $21.7 million cash balance against the projected burn rate to confirm the Q3 2025 liquidity timeline.
- Internal Control Remediation: Monitor progress on remediating material weaknesses in financial reporting controls, specifically regarding segregation of duties and system access.
- Clinical Data Readouts: Track the December 2024 DA-1241 and Q1 2025 DA-1726 data readouts, as these are critical for future valuation and funding.
- Dilution Risk: Review the terms of the outstanding warrants (Series A, Series B, and Pre-Funded Warrants) issued in June 2024, which represent significant potential dilution upon exercise.
- Related Party Transactions: Review the ongoing Shared Services Agreement with Dong-A ST Co., Ltd., which accounts for a significant portion of R&D expenses and related party payables ($3.45 million).